Keren Haruvi is President of Sandoz US and Head of North America, leading Sandoz’ largest commercial and country organization – the United States – as well as Canada. Keren was appointed to the role in 2021, and she is also a member of the Novartis Country Leadership Team and the Global Sandoz Executive Committee.

Prior to joining Sandoz, Keren served as Global Head of M&A at Novartis International AG between 2017 and 2020. Her career began at Teva Pharmaceutical Industries, most recently as Senior VP, Global Business Development and Alliance Management.

Keren is a value creator in the biopharmaceutical space. She brings over 20 years of experience in the pharmaceutical industry marked by success leading major M&A deals, enterprise innovations, and complex market strategies for large-scale, sustainable growth. 

I live with a strong sense of urgency because life is happening in real-time and I don’t delay taking on a challenge or seizing an opportunity to provide and ask for feedback. Stepping up, managing and leading an organization – especially as we prepare to be a standalone company – takes focus, and mine is on growing an inclusive, diverse and entrepreneurial culture as we strive to increase our portfolio of generic and biosimilar medicines and support policies that improve patient access. My goal is for Sandoz to emerge as a stronger organization with an enhanced understanding of the needs of the diverse communities we serve.

Keren holds an MBA in Finance from Bar-Ilan University and Bachelor’s degrees in both Economics and Chemistry from Tel Aviv University. Outside of work, Keren enjoys spending time with her 5 children. She is an avid runner with one marathon and three half-marathons under her belt.